The company priced 16,750,000 shares at $18.00 each, with delivery expected on or about May 4, 2026. It had net losses of $63.9 million in 2025 and no approved products.
Hemab Therapeutics Holdings, Inc. filed a Form S-1 on April 10, 2026, with the share count and price range left blank. Its lead drug has had serious thrombosis events, and the company reported a net loss of $63.9 million for 2025.
Questions about Hemab Therapeutics Holdings
When did Hemab Therapeutics Holdings go public?
Our latest story on this, dated May 1, 2026: "Hemab Therapeutics Holdings prices $301,500,000 IPO at $18.00 per share". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Hemab Therapeutics Holdings?
Hemab Therapeutics Holdings, Inc. trades under the ticker COAG on NASDAQ.
Where is Hemab Therapeutics Holdings listed?
Hemab Therapeutics Holdings, Inc. is listed on NASDAQ.
What is the SEC CIK of Hemab Therapeutics Holdings?
The SEC Central Index Key (CIK) for Hemab Therapeutics Holdings, Inc. is 2114044. Its filings are on SEC EDGAR.
How many shares does Hemab Therapeutics Holdings have outstanding?
46,712,117 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-11.
Which country or territory is Hemab Therapeutics Holdings listed under?
Our directory records Hemab Therapeutics Holdings, Inc. under United States.
What does Hemab Therapeutics Holdings do?
Our directory classifies Hemab Therapeutics Holdings, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Hemab Therapeutics Holdings?
The ISIN recorded for Hemab Therapeutics Holdings, Inc. is US4234941031.
Does aibio.space cover Hemab Therapeutics Holdings?
aibio.space lists Hemab Therapeutics Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Hemab Therapeutics Holdings incorporated?
SEC records list its state or country of incorporation as DE.
What is the latest Hemab Therapeutics Holdings (COAG) stock news?
Our latest story on Hemab Therapeutics Holdings, dated May 1, 2026: "Hemab Therapeutics Holdings prices $301,500,000 IPO at $18.00 per share". The company priced 16,750,000 shares at $18.00 each, with delivery expected on or about May 4, 2026. It had net losses of $63.9 million in 2025 and no approved products. Source.
What is Hemab Therapeutics Holdings's latest stock offering or financing news?
Our latest financing story, dated May 1, 2026: "Hemab Therapeutics Holdings prices $301,500,000 IPO at $18.00 per share". The company priced 16,750,000 shares at $18.00 each, with delivery expected on or about May 4, 2026. It had net losses of $63.9 million in 2025 and no approved products. Source.
Who were the underwriters or placement agents on Hemab Therapeutics Holdings's offering?
From our story: Goldman Sachs & Co. LLC, Jefferies and Evercore ISI are the joint book-running managers. Source.
How much cash does Hemab Therapeutics Holdings have?
From our story of May 1, 2026: At December 31, 2025 it held cash, cash equivalents and marketable securities of $185,485 thousand, shown as $460,130 thousand after the offering. Source.
Is Hemab Therapeutics Holdings a smaller reporting company?
SEC records list Hemab Therapeutics Holdings, Inc.'s filer category as: <br>Emerging growth company.
Investor discussion: Hemab Therapeutics Holdings
Members talk about Hemab Therapeutics Holdings (COAG). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Hemab Therapeutics Holdings, newest first. Each line links the filing it comes from.
Filed a registration statement for a share offering. SEC Form S-1. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:COAG on TradingView.
SEC filings and registration
SEC name
Hemab Therapeutics Holdings, Inc.
CIK
2114044
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
COAG (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
101 MAIN STREET, CAMBRIDGE, MA, 02142
Phone
45 2138 7627
Shares outstanding
46,712,117 as of 2026-07-31 (10-Q filed 2026-08-11)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Hemab Therapeutics Holdings, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker COAG, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio